Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas

I Ray-Coquard, H Ghesquière, T Bachelot, C Borg, P Biron, C Sebban, A LeCesne, F Chauvin, J Y Blay, ELYPSE Study Group, I Ray-Coquard, H Ghesquière, T Bachelot, C Borg, P Biron, C Sebban, A LeCesne, F Chauvin, J Y Blay, ELYPSE Study Group

Abstract

1-5% of cancer patients treated with cytotoxic chemotherapy die within a month after the administration of chemotherapy. Risk factors for these early deaths (ED) are not well known. The purpose of this study was to establish a risk model for ED after chemotherapy applicable to all tumour types. The model was delineated in a series of 1051 cancer patients receiving a first course of chemotherapy in the Department of Medicine of the Centre Léon Bérard (CLB) in 1996 (CLB-1996 cohort), and then validated in a series of patients treated in the same department in 1997 (CLB-1997), in a prospective cohort of patients with aggressive non-Hodgkin's lymphoma (NHL) (CLB-NHL), and in a prospective cohort of patients with metastatic breast cancer (MBC series) receiving first-line chemotherapy. In the CLB-1996 series, 43 patients (4.1%) experienced early. In univariate analysis, age > 60, PS > 1, lymphocyte (ly) count <or= 700 microl(-1)immediately prior to chemotherapy (d1), d1-platelet count <or= 150 Gl(-1), and the type of chemotherapy were significantly correlated to the risk of early death (P<or= 0.01). Using logistic regression, PS > 1 (hazard ratio 3.9 (95% Cl 2.0-7.5)) and d1-ly count <or= 700 microl(-1) (3.1 (95% Cl 1.6-5.8)) were identified as independent risk factors for ED. The calculated probability of ED was 20% (95% Cl 10-31) in patients with both risk factors, 6% (95% Cl 4-9) for patients with only 1 risk factor, and 1.7% (95% Cl 0.9-3) for patients with none of these 2 risk factors. In the CLB-97, CLB-NHL and MBC validation series, the observed incidences of early death in patients with both risk factors were 19%, 25% and 40% respectively and did not differ significantly from those calculated in the model. In conclusion, poor performance status and lymphopenia identify a subgroup of patients at high risk for early death after chemotherapy.

Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.

References

    1. Drugs Aging. 1997 Jan;10(1):34-49
    1. Cancer Res. 1996 Dec 1;56(23):5499-505
    1. J Clin Oncol. 1998 Jun;16(6):2065-9
    1. Blood. 1998 Jul 15;92(2):405-10
    1. J Clin Oncol. 1999 Sep;17(9):2840-6
    1. Clin Cancer Res. 2000 Apr;6(4):1351-64
    1. Nat Med. 2000 May;6(5):493-5
    1. Cancer. 1970 Jan;25(1):135-40
    1. Curr Concepts Nutr. 1977;6:7-13
    1. JAMA. 1979 Aug 17;242(7):623-32
    1. Surg Clin North Am. 1981 Jun;61(3):437-63
    1. Eur J Cancer Clin Oncol. 1984 Jan;20(1):55-60
    1. Br J Cancer. 1989 May;59(5):801-4
    1. Bull Cancer. 1990;77(9):941-7
    1. Cancer. 1991 Feb 1;67(3):716-21
    1. N Engl J Med. 1993 Apr 8;328(14):1002-6
    1. J Clin Oncol. 1993 Jul;11(7):1276-85
    1. N Engl J Med. 1993 Sep 30;329(14):987-94
    1. Lung Cancer. 1993 Dec;10(3-4):189-97
    1. Nat Med. 1996 Mar;2(3):317-22
    1. J Clin Oncol. 1996 Feb;14(2):636-43
    1. Nat Med. 1996 Dec;2(12):1361-6
    1. Cancer. 1998 Jan 1;82(1):116-26

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться